HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
JNJ
Johnson & Johnson
JNJ's fundamentals are mixed, but it looks expensive: trading at 43x earnings, above its usual 24x. Its downside scenario is about eight times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
JNJ Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
JNJ's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
JNJ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $114 | -60% |
| Fair | 24x | $159 | -44% |
| Forward | 25x | $284 | — |
| Expensive | 29x | $191 | -33% |
| Current | 43x | $284 | — |
Historical ranges are pointers, not guarantees.
JNJ's PE is in its expensive range at 43x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
JNJ Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Moderate |
JNJ has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
JNJ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.26 | +71% |
| Q3 2026 | $6.58 | -36% |
| Q2 2026 | $8.61 | -7.9% |
| Q1 2026 | $8.63 | -4% |
| Q4 2025 | $11.03 | +91% |
| Q3 2025 | $10.36 | +71% |
| Q2 2025 | $9.35 | -38% |
| Q1 2025 | $8.99 | -41% |
| Q4 2024 | $5.79 | -58% |
JNJ has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over JNJ on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
JNJ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.4B | +5.9% |
| Q2 2026 | $25.3B | +6.6% |
| Q1 2026 | $24.1B | +9.9% |
| Q4 2025 | $24.6B | +9.1% |
| Q3 2025 | $24B | +6.8% |
| Q2 2025 | $23.7B | +5.8% |
| Q1 2025 | $21.9B | +2.4% |
| Q4 2024 | $22.5B | +5.3% |
JNJ's revenue has grown year over year for nine quarters in a row: $25.4B last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.1% | -31 points |
| Q2 2026 | 27% | -0.7 points |
| Q1 2026 | 25% | -37 points |
| Q4 2025 | 20% | +3 points |
| Q3 2025 | 31% | +16 points |
| Q2 2025 | 27% | +1.7 points |
| Q1 2025 | 62% | +45 points |
| Q4 2024 | 17% | -5.3 points |
JNJ has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over JNJ on cash flow, with more consistent year-over-year improvement.
JNJ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.4B | -21% |
| Q2 2026 | $7.3B | +157% |
| Q1 2026 | $1.5B | -57% |
| Q4 2025 | $5.5B | +1.9% |
| Q3 2025 | $8B | +15% |
| Q2 2025 | $2.8B | -39% |
| Q1 2025 | $3.4B | +19% |
| Q4 2024 | $5.4B | -14% |
JNJ's free cash flow has been positive every quarter for seven years: $20.6B over the past year, up 5.1% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over JNJ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
JNJ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +8.5M shares |
| 1 year | +0.8% | +20M shares |
| 3 years | -4% | -101M shares |
| 5 years | -8.5% | -226M shares |
| Available history | -8.8% | -236M shares |
JNJ has 2.4B diluted shares, up 0.8% from a year ago, despite $7.9B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.7B |
| Q2 2026 | $221M |
| Q1 2026 | $4B |
| Q4 2025 | $1.9B |
| Q3 2025 | $1.9B |
| Q2 2025 | — |
| Q1 2025 | $2.1B |
| Q4 2024 | $282M |
JNJ spent $7.9B buying back its own shares over the past year, up 83% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
JNJ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 0.9x | Very low |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.4x | Very low |
| Q4 2024 | 0.5x | Very low |
JNJ's net debt is about 1.1 years of its operating earnings (EBITDA), up from less than a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
JNJ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.5 | Neutral |
| Stochastic | 84.7 | Overbought |
JNJ's weekly RSI is 65 (neutral) and its Stochastic is 85 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
JNJ PE vs Healthcare Sector
| Metric | JNJ | Sector median | Relative |
|---|---|---|---|
| PE | 43x | 26x | 67% above |
| PE % | 100 | 29 | 71 pts above |
JNJ is trading at 43x earnings, a 67% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
JNJ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $267.6 | 5.9% above |
| 20 week MA | $265.1 | 6.9% above |
| 50 week MA | $243.5 | 16% above |
| 100 week MA | $204.7 | 39% above |
| 200 week MA | $181.3 | 56% above |
JNJ has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
JNJ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $145.8 | $152.5 | +4.6% |
| 2021 | $152.5 | $168.3 | +10% |
| 2022 | $168.3 | $177.5 | +5.5% |
| 2023 | $177.5 | $156.7 | -12% |
| 2024 | $156.7 | $145.1 | -7.5% |
| 2025 | $145.1 | $207.6 | +43% |
| 2026 YTD | $207.6 | $283.5 | +37% |
JNJ has the edge over HIMS on returns for 2026, with the stronger performance.